Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari Christopher J Coughlin. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa Christopher J Coughlin telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Keamanan | Judul | Kepemilikan Terakhir yang Dilaporkan |
---|---|---|
US:CNC / Centene Corporation | Director | 11,436 |
US:KRTX / Karuna Therapeutics, Inc. | Director | 0 |
US:PBH / Prestige Consumer Healthcare Inc. | Director | 13,218 |
US:US00C4W1JQ50 / Alexion Pharmaceuticals, Inc. | Director | 0 |
US:ACT / Enact Holdings, Inc. | Director | 0 |
NO:US23329PAB67 / DNB Bank ASA | Director | 38,317 |
US:HOLX / Hologic, Inc. | Director | 6,816 |
US:COV / | Director | 0 |
Director | 0 | |
US:DPRX / Dipexium Pharmaceuticals, Inc. | Director | 109,309 |
US:TYC / Tyco International plc | EVP and CFO | 184,700 |
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh Christopher J Coughlin. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam ACT / Enact Holdings, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACT / Enact Holdings, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ACT / Enact Holdings, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACT / Enact Holdings, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam PBH / Prestige Consumer Healthcare Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACT / Enact Holdings, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam PBH / Prestige Consumer Healthcare Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACT / Enact Holdings, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh Christopher J Coughlin sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-07-02 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 556 | 11,436 | 5.11 | ||||
2025-05-14 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 3,579 | 10,880 | 49.02 | ||||
2025-04-02 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 500 | 7,301 | 7.35 | ||||
2025-01-03 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 497 | 6,801 | 7.88 | ||||
2024-12-17 |
|
4 | CNC |
CENTENE CORP
Common Stock |
P - Purchase | 10,000 | 36,358 | 37.94 | 59.44 | 594,400 | 2,161,115 | |
2024-10-02 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 402 | 26,358 | 1.55 | ||||
2024-07-02 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 452 | 25,956 | 1.77 | ||||
2024-05-24 | 3/A | CNC |
CENTENE CORP
Common Stock |
878 | ||||||||
2024-05-24 |
|
4 | CNC |
CENTENE CORP
Common Stock |
S - Sale | -878 | 0 | -100.00 | 76.74 | -67,382 | ||
2024-05-16 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 2,916 | 25,504 | 12.91 | ||||
2024-04-02 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 389 | 22,588 | 1.75 | ||||
2024-03-18 |
|
4 | KRTX |
Karuna Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -990 | 0 | -100.00 | 330.00 | -326,700 | ||
2024-01-03 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 502 | 22,199 | 2.32 | ||||
2023-10-03 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 545 | 21,697 | 2.58 | ||||
2023-07-05 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 544 | 21,152 | 2.64 | ||||
2023-06-22 |
|
4 | KRTX |
Karuna Therapeutics, Inc.
Common Stock |
A - Award | 990 | 990 | |||||
2023-05-12 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 2,947 | 20,608 | 16.69 | ||||
2023-04-04 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 511 | 17,661 | 2.98 | ||||
2023-01-04 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 444 | 17,151 | 2.66 | ||||
2022-10-04 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 406 | 16,707 | 2.49 | ||||
2022-08-03 |
|
4 | PBH |
Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share |
A - Award | 2,495 | 13,218 | 23.27 | ||||
2022-07-05 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 436 | 16,301 | 2.75 | ||||
2022-05-03 |
|
4 | CNC |
CENTENE CORP
Common Stock |
P - Purchase | 12,000 | 15,865 | 310.48 | 81.37 | 976,440 | 1,290,932 | |
2022-04-28 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 2,323 | 3,865 | 150.65 | ||||
2022-04-04 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 442 | 1,542 | 40.18 | 82.02 | 36,250 | 126,472 | |
2022-02-09 |
|
4 | CNC |
CENTENE CORP
Common Stock Option (right to buy) |
A - Award | 10,000 | 10,000 | |||||
2022-02-09 |
|
4 | CNC |
CENTENE CORP
Common Stock |
A - Award | 1,100 | 1,100 | |||||
2022-01-14 | 3 | CNC |
CENTENE CORP
No Securities Beneficially Owned |
0 | ||||||||
2021-08-05 |
|
4 | PBH |
Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share |
A - Award | 2,808 | 10,723 | 35.48 | ||||
2021-07-23 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Option to Purchase Common Stock |
D - Sale to Issuer | -2,343 | 0 | -100.00 | 155.01 | -363,188 | ||
2021-07-23 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Option to Purchase Common Stock |
D - Sale to Issuer | -2,706 | 0 | -100.00 | 167.97 | -454,527 | ||
2021-07-23 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Option to Purchase Common Stock |
D - Sale to Issuer | -2,294 | 0 | -100.00 | 138.86 | -318,545 | ||
2021-07-23 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share |
D - Sale to Issuer | -42,347 | 0 | -100.00 | ||||
2021-06-23 |
|
4 | KRTX |
Karuna Therapeutics, Inc.
Option (right to buy) |
A - Award | 8,500 | 8,500 | |||||
2021-05-24 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share |
A - Award | 729 | 42,347 | 1.75 | ||||
2021-05-24 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share |
A - Award | 1,962 | 41,618 | 4.95 | ||||
2020-08-06 |
|
4 | PBH |
Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share |
A - Award | 3,732 | 7,915 | 89.22 | ||||
2020-05-18 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share |
A - Award | 2,774 | 39,656 | 7.52 | ||||
2020-05-18 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share |
A - Award | 3,468 | 36,882 | 10.38 | ||||
2020-05-11 |
|
4 | AGN |
Allergan plc
Stock Options |
D - Sale to Issuer | -9,446 | 0 | -100.00 | ||||
2020-05-11 |
|
4 | AGN |
Allergan plc
Stock Options |
D - Sale to Issuer | -3,691 | 0 | -100.00 | ||||
2020-05-11 |
|
4 | AGN |
Allergan plc
Stock Options |
D - Sale to Issuer | -2,790 | 0 | -100.00 | ||||
2020-05-11 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
D - Sale to Issuer | -16,532 | 0 | -100.00 | ||||
2020-05-11 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
D - Sale to Issuer | -9,538 | 16,542 | -36.57 | ||||
2020-05-11 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
D - Sale to Issuer | -471 | 26,080 | -1.77 | ||||
2020-05-04 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -991 | 16,542 | -5.65 | 189.74 | -188,032 | 3,138,679 | |
2020-04-28 |
|
4 | KRTX |
Karuna Therapeutics, Inc.
Option (right to buy) |
A - Award | 25,000 | 25,000 | |||||
2020-02-13 |
|
5 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
G - Gift | -9,538 | 12,776 | -42.74 | ||||
2019-08-01 | 3 | PBH |
Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share |
0 | ||||||||
2019-08-01 |
|
4 | PBH |
Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share |
A - Award | 4,183 | 4,183 | |||||
2019-05-17 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share |
A - Award | 2,181 | 33,414 | 6.98 | ||||
2019-05-17 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share |
A - Award | 2,726 | 31,233 | 9.56 | ||||
2019-05-02 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
A - Award | 2,064 | 17,080 | 13.75 | 145.33 | 299,961 | 2,482,236 | |
2019-05-02 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -953 | 15,016 | -5.97 | 147.00 | -140,091 | 2,207,352 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 300 | 16,431 | 1.86 | 190.63 | 57,189 | 3,132,242 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 517 | 16,131 | 3.31 | 190.64 | 98,561 | 3,075,214 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 4,889 | 15,614 | 45.59 | 190.68 | 932,235 | 2,977,278 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 222 | 10,725 | 2.11 | 190.67 | 42,329 | 2,044,936 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 816 | 10,503 | 8.42 | 190.66 | 155,579 | 2,002,502 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 100 | 9,687 | 1.04 | 190.65 | 19,065 | 1,846,827 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 68 | 9,587 | 0.71 | 190.62 | 12,962 | 1,827,474 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 200 | 9,519 | 2.15 | 190.61 | 38,122 | 1,814,417 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 400 | 9,319 | 4.48 | 190.60 | 76,240 | 1,776,201 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 356 | 8,919 | 4.16 | 190.59 | 67,850 | 1,699,872 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 100 | 8,563 | 1.18 | 190.58 | 19,058 | 1,631,937 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 27 | 8,463 | 0.32 | 190.57 | 5,145 | 1,612,794 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 705 | 8,436 | 9.12 | 190.56 | 134,345 | 1,607,564 | |
2018-09-07 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 1,300 | 7,731 | 20.21 | 190.55 | 247,715 | 1,473,142 | |
2018-05-11 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
A - Award | 2,174 | 28,507 | 8.26 | ||||
2018-05-04 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
A - Award | 1,985 | 6,431 | 44.65 | 151.07 | 299,874 | 971,531 | |
2018-05-04 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
G - Gift | -10,000 | 4,446 | -69.22 | ||||
2018-05-02 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
P - Purchase | 10,000 | 26,333 | 61.23 | 120.79 | 1,207,900 | 3,180,763 | |
2017-12-05 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
P - Purchase | 10,000 | 14,446 | 224.92 | 163.30 | 1,633,000 | 2,359,032 | |
2017-12-05 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
A - Award | 10,000 | 16,333 | 157.90 | 112.75 | 1,127,500 | 1,841,546 | |
2017-06-16 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
P - Purchase | 2,000 | 6,333 | 46.16 | 117.10 | 234,200 | 741,594 | |
2017-05-12 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
A - Award | 2,030 | 4,333 | 88.15 | ||||
2017-05-05 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
A - Award | 1,223 | 4,446 | 37.95 | 245.25 | 299,941 | 1,090,382 | |
2017-05-05 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -668 | 3,223 | -17.17 | 243.76 | -162,832 | 785,638 | |
2017-03-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 175 | 38,317 | 0.46 | 40.29 | 7,054 | 1,543,796 | |
2017-03-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 75 | 16,536 | 0.45 | 107.81 | 8,048 | 1,782,736 | |
2017-03-09 |
|
4 | HOLX |
HOLOGIC INC
Non-qualified Stock Option (Right to Buy) |
A - Award | 6,816 | 6,816 | |||||
2017-03-09 |
|
4 | HOLX |
HOLOGIC INC
Restricted Stock Unit Award (Right To Receive) |
M - Exercise | -2,427 | 0 | -100.00 | ||||
2017-03-09 |
|
4 | HOLX |
HOLOGIC INC
Common Stock |
A - Award | 2,206 | 7,633 | 40.65 | ||||
2017-03-09 |
|
4 | HOLX |
HOLOGIC INC
Common Stock |
M - Exercise | 2,427 | 5,427 | 80.90 | ||||
2017-02-02 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 728 | 38,142 | 1.95 | 45.73 | 33,301 | 1,744,235 | |
2017-01-27 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Non-Qualified Stock Option (right to buy) |
M - Exercise | -2,086 | 0 | -100.00 | ||||
2017-01-27 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
M - Exercise | 2,086 | 18,547 | 12.67 | 88.04 | 183,651 | 1,632,901 | |
2016-12-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 144 | 37,414 | 0.39 | 46.00 | 6,605 | 1,721,035 | |
2016-12-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 63 | 16,461 | 0.38 | 122.96 | 7,698 | 2,024,035 | |
2016-09-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 133 | 37,270 | 0.36 | 49.52 | 6,580 | 1,845,622 | |
2016-09-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 57 | 16,399 | 0.35 | 134.56 | 7,670 | 2,206,603 | |
2016-08-17 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -100 | 3,891 | -2.51 | 254.05 | -25,405 | 988,509 | |
2016-08-09 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
A - Award | 201 | 3,991 | 5.30 | 248.31 | 49,910 | 991,005 | |
2016-07-05 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 2,300 | 37,137 | 6.60 | 45.44 | 104,500 | 1,687,521 | |
2016-06-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phanton Stock Units - Deferred Compensation |
A - Award | 131 | 34,838 | 0.38 | 46.88 | 6,159 | 1,633,188 | |
2016-06-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 61 | 16,342 | 0.37 | 126.04 | 7,641 | 2,059,620 | |
2016-05-13 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 2,294 | 2,294 | 138.86 | 318,545 | 318,545 | ||
2016-05-13 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
A - Award | 835 | 2,303 | 56.88 | ||||
2016-05-09 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
A - Award | 1,188 | 3,790 | 45.66 | 210.34 | 249,884 | 797,189 | |
2016-05-06 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 1,087 | 16,281 | 7.15 | ||||
2016-03-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 164 | 34,706 | 0.48 | 37.41 | 6,147 | 1,298,360 | |
2016-03-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 72 | 15,194 | 0.47 | 98.98 | 7,082 | 1,503,828 | |
2016-03-04 |
|
4 | HOLX |
HOLOGIC INC
Restricted Stock Unit Award (Right To Receive) |
A - Award | 2,427 | 2,427 | |||||
2016-03-04 |
|
4 | HOLX |
HOLOGIC INC
Non-qualified Stock Option (Right to Buy) |
A - Award | 7,402 | 7,402 | |||||
2016-03-04 | 3 | HOLX |
HOLOGIC INC
Common Stock |
6,000 | ||||||||
2016-03-04 | 3 | HOLX |
HOLOGIC INC
Common Stock |
6,000 | ||||||||
2016-02-02 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 2,837 | 34,542 | 8.95 | 36.84 | 104,500 | 1,272,524 | |
2015-12-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 140 | 31,705 | 0.44 | 38.55 | 5,382 | 1,222,240 | |
2015-12-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 65 | 15,122 | 0.43 | 103.68 | 6,758 | 1,567,898 | |
2015-11-10 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Non-Qualified Stock Option - right to buy |
M - Exercise | -2,330 | 0 | -100.00 | ||||
2015-11-10 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
S - Sale | -2,330 | 15,057 | -13.40 | 112.50 | -262,134 | 1,694,003 | |
2015-11-10 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
M - Exercise | 2,330 | 17,387 | 15.47 | 71.28 | 166,071 | 1,239,279 | |
2015-09-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 136 | 31,566 | 0.43 | 39.26 | 5,351 | 1,239,270 | |
2015-09-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 64 | 15,057 | 0.43 | 104.56 | 6,729 | 1,574,390 | |
2015-08-25 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -124 | 2,602 | -4.55 | 298.57 | -37,023 | 776,879 | |
2015-08-18 |
|
4 | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -100 | 2,726 | -3.54 | 314.50 | -31,450 | 857,327 | |
2015-07-01 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 2,296 | 31,429 | 7.88 | 45.52 | 104,500 | 1,430,668 | |
2015-06-30 |
|
4/A | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
A - Award | 826 | 2,826 | 41.30 | 302.30 | 249,700 | 854,300 | |
2015-06-30 |
|
4/A | AGN |
Allergan plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -334 | 2,000 | -14.31 | 303.38 | -101,329 | 606,760 | |
2015-06-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phanton Stock Units - Deferred |
A - Award | 102 | 29,134 | 0.35 | 48.14 | 4,931 | 1,402,498 | |
2015-06-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 52 | 14,993 | 0.35 | 129.73 | 6,705 | 1,945,033 | |
2015-06-08 |
|
4 | ACT |
Actavis plc
Ordinary Shares, par value $0.0001 |
A - Award | 826 | 2,826 | 41.30 | 302.30 | 249,700 | 854,300 | |
2015-06-08 |
|
4 | ACT |
Actavis plc
Ordinary Shares, par value $0.0001 |
F - Taxes | -334 | 2,000 | -14.31 | 303.38 | -101,329 | 606,760 | |
2015-05-08 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 2,343 | 2,343 | 155.01 | 363,188 | 363,188 | ||
2015-05-08 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
A - Award | 700 | 1,468 | 91.15 | ||||
2015-05-08 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 954 | 14,941 | 6.82 | ||||
2015-03-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred |
A - Award | 104 | 29,031 | 0.36 | 47.20 | 4,911 | 1,370,277 | |
2015-03-13 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 49 | 13,987 | 0.35 | 127.20 | 6,241 | 1,779,249 | |
2015-02-03 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 2,431 | 28,927 | 9.17 | 42.99 | 104,500 | 1,243,583 | |
2015-01-28 |
|
4 | COV |
Covidien plc
Stock Option (Right to Buy) |
D - Sale to Issuer | -55,004 | 0 | -100.00 | ||||
2015-01-28 |
|
4 | COV |
Covidien plc
Stock Option (Right to Buy) |
D - Sale to Issuer | -55,004 | 0 | -100.00 | ||||
2015-01-28 |
|
4 | COV |
Covidien plc
Stock Option (Right to Buy) |
D - Sale to Issuer | -10,521 | 0 | -100.00 | ||||
2015-01-28 |
|
4 | COV |
Covidien plc
Stock Option (Right to Buy) |
D - Sale to Issuer | -14,109 | 0 | -100.00 | ||||
2015-01-28 |
|
4 | COV |
Covidien plc
Ordinary Shares |
D - Sale to Issuer | -7,970 | 0 | -100.00 | ||||
2015-01-28 |
|
4 | COV |
Covidien plc
Ordinary Shares |
D - Sale to Issuer | -49,475 | 0 | -100.00 | ||||
2014-12-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 100 | 26,496 | 0.38 | 42.50 | 4,271 | 1,126,100 | |
2014-12-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 51 | 13,938 | 0.37 | 114.86 | 5,914 | 1,600,871 | |
2014-11-03 |
|
4 | ACT |
Actavis plc
Ordinary Shares, par value $0.0001 |
A - Award | 694 | 18,261 | 3.95 | 243.21 | 168,788 | 4,441,258 | |
2014-09-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 98 | 26,396 | 0.37 | 43.67 | 4,259 | 1,152,712 | |
2014-09-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 50 | 13,887 | 0.36 | 117.04 | 5,892 | 1,625,369 | |
2014-07-24 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 2,706 | 2,706 | 167.97 | 454,527 | 454,527 | ||
2014-07-24 |
|
4 | ALXN |
ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share |
A - Award | 768 | 768 | |||||
2014-07-03 |
|
4 | FRX |
Forest Laboratories, LLC
Stock Option (Right to Buy) |
D - Sale to Issuer | -5,909 | 0 | -100.00 | ||||
2014-07-03 |
|
4 | FRX |
Forest Laboratories, LLC
Stock Option (Right to Buy) |
D - Sale to Issuer | -7,815 | 0 | -100.00 | ||||
2014-07-03 |
|
4 | FRX |
Forest Laboratories, LLC
Stock Option (Right to Buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
2014-07-03 |
|
4 | FRX |
Forest Laboratories, LLC
Restricted Stock |
D - Sale to Issuer | -2,406 | 0 | -100.00 | ||||
2014-07-03 |
|
4 | FRX |
Forest Laboratories, LLC
Common Stock |
D - Sale to Issuer | -1,527 | 0 | -100.00 | ||||
2014-07-03 |
|
4 | ACT |
Actavis plc
Stock Option (Right to Buy) |
A - Award | 2,790 | 2,790 | |||||
2014-07-03 |
|
4 | ACT |
Actavis plc
Stock Option (Right to Buy) |
A - Award | 3,691 | 3,691 | |||||
2014-07-03 |
|
4 | ACT |
Actavis plc
Stock Option (Right to Buy) |
A - Award | 9,446 | 9,446 | |||||
2014-07-03 |
|
4 | ACT |
Actavis plc
Ordinary Shares, par value $0.0001 |
A - Award | 1,640 | 1,640 | |||||
2014-07-02 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 2,501 | 26,298 | 10.51 | 41.79 | 104,500 | 1,099,012 | |
2014-06-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 99 | 23,798 | 0.42 | 38.88 | 3,844 | 925,260 | |
2014-06-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 57 | 13,836 | 0.41 | 103.94 | 5,891 | 1,438,151 | |
2014-05-23 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 420 | 49,446 | 0.86 | ||||
2014-05-09 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 1,141 | 13,780 | 9.03 | ||||
2014-03-21 |
|
4 | COV |
Covidien plc
Ordinary Shares |
F - Taxes | -1,046 | 49,016 | -2.09 | 70.68 | -73,931 | 3,464,451 | |
2014-03-21 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 2,264 | 50,062 | 4.74 | ||||
2014-03-20 |
|
4 | DPRX |
Dipexium Pharmaceuticals, Inc.
Common Stock, par value $.001 per share |
P - Purchase | 2,083 | 109,309 | 1.94 | 12.00 | 24,996 | 1,311,708 | |
2014-03-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 104 | 23,699 | 0.44 | 36.77 | 3,823 | 871,411 | |
2014-03-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 54 | 12,639 | 0.43 | 98.08 | 5,341 | 1,239,601 | |
2014-03-12 | 3 | DPRX |
Dipexium Pharmaceuticals, LLC
Common Stock, par value $.001 per share |
214,452 | ||||||||
2014-03-12 | 3 | DPRX |
Dipexium Pharmaceuticals, LLC
Common Stock, par value $.001 per share |
214,452 | ||||||||
2014-02-24 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 12 | 47,798 | 0.03 | 71.28 | 855 | 3,407,041 | |
2014-02-04 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 2,544 | 23,595 | 12.08 | 41.08 | 104,500 | 969,282 | |
2013-12-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 72 | 21,051 | 0.34 | 42.99 | 3,087 | 904,990 | |
2013-12-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 42 | 12,584 | 0.33 | 116.06 | 4,839 | 1,460,524 | |
2013-11-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Non-Qualified Stock Option - right to buy |
M - Exercise | -2,746 | 0 | -100.00 | ||||
2013-11-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Non-Qualified Stock Option - right to buy |
M - Exercise | -1,573 | 0 | -100.00 | ||||
2013-11-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
S - Sale | -4,319 | 12,543 | -25.61 | 110.75 | -478,335 | 1,389,100 | |
2013-11-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
M - Exercise | 2,746 | 16,862 | 19.45 | 60.54 | 166,229 | 1,020,712 | |
2013-11-14 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
M - Exercise | 1,573 | 14,116 | 12.54 | 59.86 | 94,160 | 844,955 | |
2013-11-07 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 13 | 47,786 | 0.03 | 64.33 | 836 | 3,074,073 | |
2013-10-24 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 1,374 | 20,979 | 7.01 | 40.02 | 55,000 | 839,595 | |
2013-09-20 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 72 | 19,605 | 0.37 | 40.32 | 2,884 | 790,476 | |
2013-09-20 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 45 | 12,543 | 0.36 | 106.96 | 4,821 | 1,341,548 | |
2013-08-16 |
|
4 | FRX |
FOREST LABORATORIES INC
Stock Option (Right to Buy) |
A - Award | 5,909 | 5,909 | |||||
2013-08-16 |
|
4 | FRX |
FOREST LABORATORIES INC
Common Stock |
A - Award | 1,761 | 3,933 | 81.08 | ||||
2013-08-16 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 11 | 47,773 | 0.02 | 61.85 | 680 | 2,954,760 | |
2013-07-19 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 248 | 47,762 | 0.52 | ||||
2013-07-03 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 1,647 | 19,534 | 9.21 | 36.74 | 60,500 | 717,662 | |
2013-06-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 70 | 17,887 | 0.40 | 37.25 | 2,626 | 666,285 | |
2013-06-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 49 | 12,497 | 0.39 | 98.79 | 4,802 | 1,234,623 | |
2013-05-07 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 8 | 47,302 | 0.02 | 64.35 | 515 | 3,043,884 | |
2013-03-22 |
|
4 | COV |
Covidien plc
Ordinary Shares |
F - Taxes | -1,052 | 47,294 | -2.18 | 65.50 | -68,906 | 3,097,757 | |
2013-03-22 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 2,214 | 48,346 | 4.80 | ||||
2013-03-18 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 86 | 17,816 | 0.48 | 30.51 | 2,622 | 543,577 | |
2013-03-18 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 59 | 12,449 | 0.47 | 81.23 | 4,778 | 1,011,219 | |
2013-02-21 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 1,453 | 12,390 | 13.29 | 82.56 | 119,952 | 1,022,858 | |
2013-02-06 |
|
4 | COV |
Covidien plc
Stock Option (Right to Buy) |
M - Exercise | -12,000 | 0 | -100.00 | ||||
2013-02-06 |
|
4 | COV |
Covidien plc
Stock Option (Right to Buy) |
M - Exercise | -12,000 | 0 | -100.00 | ||||
2013-02-06 |
|
4 | COV |
Covidien plc
Stock Option (Right to Buy) |
M - Exercise | -12,000 | 0 | -100.00 | ||||
2013-02-06 |
|
4 | COV |
Covidien plc
Ordinary Shares |
S - Sale | -36,000 | 0 | -100.00 | 62.05 | -2,233,800 | ||
2013-02-06 |
|
4 | COV |
Covidien plc
Ordinary Shares |
M - Exercise | 12,000 | 36,000 | 50.00 | 36.99 | 443,884 | 1,331,651 | |
2013-02-06 |
|
4 | COV |
Covidien plc
Ordinary Shares |
M - Exercise | 12,000 | 24,000 | 100.00 | 45.45 | 545,364 | 1,090,728 | |
2013-02-06 |
|
4 | COV |
Covidien plc
Ordinary Shares |
M - Exercise | 12,000 | 12,000 | 45.66 | 547,890 | 547,890 | ||
2013-02-05 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 1,950 | 17,730 | 12.36 | 31.03 | 60,500 | 550,175 | |
2012-12-28 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 12 | 46,132 | 0.03 | 57.35 | 688 | 2,645,670 | |
2012-12-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 73 | 15,781 | 0.46 | 30.26 | 2,209 | 477,524 | |
2012-12-17 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 49 | 10,937 | 0.45 | 80.90 | 3,968 | 884,750 | |
2012-11-07 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 13 | 46,120 | 0.03 | 55.65 | 723 | 2,566,578 | |
2012-09-20 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 71 | 15,708 | 0.45 | 31.27 | 2,205 | 491,180 | |
2012-09-20 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 47 | 10,888 | 0.44 | 83.39 | 3,950 | 907,947 | |
2012-08-27 |
|
4 | FRX |
FOREST LABORATORIES INC
Stock Option (Right to Buy) |
A - Award | 7,815 | 7,815 | |||||
2012-08-27 |
|
4 | FRX |
FOREST LABORATORIES INC
Common Stock |
A - Award | 2,172 | 2,172 | |||||
2012-08-20 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 10 | 46,107 | 0.02 | 57.59 | 576 | 2,655,302 | |
2012-07-05 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 1,836 | 15,229 | 13.71 | 26.96 | 49,500 | 410,578 | |
2012-06-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 73 | 13,393 | 0.55 | 25.56 | 1,879 | 342,328 | |
2012-06-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 58 | 10,841 | 0.54 | 67.32 | 3,928 | 729,734 | |
2012-05-11 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 134 | 13,320 | 1.02 | 23.85 | 3,203 | 317,673 | |
2012-05-09 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 11 | 46,097 | 0.02 | 54.25 | 597 | 2,500,762 | |
2012-03-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 50 | 13,185 | 0.38 | 32.18 | 1,608 | 424,303 | |
2012-03-16 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 46 | 10,782 | 0.42 | 85.90 | 3,911 | 926,248 | |
2012-03-14 |
|
4 | COV |
Covidien plc
Ordinary Shares |
F - Taxes | -1,033 | 46,086 | -2.19 | 53.89 | -55,668 | 2,483,575 | |
2012-03-14 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 2,691 | 47,119 | 6.06 | ||||
2012-03-05 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Phantom Stock Units - Deferred Compensation |
A - Award | 1,590 | 13,135 | 13.77 | 31.14 | 49,500 | 409,034 | |
2012-02-24 |
|
4 | COV |
Covidien plc
Ordinary Shares |
A - Award | 11 | 44,428 | 0.02 | 52.45 | 577 | 2,330,249 | |
2012-02-15 |
|
4 | DNB |
DUN & BRADSTREET CORP/NW
Common Stock |
A - Award | 1,517 | 10,737 | 16.45 | 79.10 | 120,002 | 849,327 | |
2008-10-09 |
|
4 | TYC |
TYCO INTERNATIONAL LTD /BER/
Stock Option (Right to Buy) |
A - Award | 184,700 | 184,700 | |||||
2008-10-09 |
|
4 | TYC |
TYCO INTERNATIONAL LTD /BER/
Performance Share Units |
A - Award | 51,700 | 94,900 | 119.68 | ||||
2005-08-08 |
|
4 | TYC |
TYCO INTERNATIONAL LTD /BER/
Common Shares |
P - Purchase | 10,000 | 110,000 | 10.00 | 27.24 | 272,400 | 2,996,400 | |
2005-03-07 | 3 | TYC |
TYCO INTERNATIONAL LTD /BER/
Common Shares |
0 |